Laekna, Inc.
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People's Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer,… Read more
Laekna, Inc. (4U4) - Net Assets
Latest net assets as of June 2025: €712.86 Million EUR
Based on the latest financial reports, Laekna, Inc. (4U4) has net assets worth €712.86 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€913.41 Million) and total liabilities (€200.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €712.86 Million |
| % of Total Assets | 78.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Laekna, Inc. - Net Assets Trend (2021–2024)
This chart illustrates how Laekna, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Laekna, Inc. (2021–2024)
The table below shows the annual net assets of Laekna, Inc. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €804.79 Million | +0.10% |
| 2023-12-31 | €803.97 Million | +142.20% |
| 2022-12-31 | €-1.91 Billion | -71.45% |
| 2021-12-31 | €-1.11 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Laekna, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 140470400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.40 Billion | 421.93% |
| Total Equity | €804.79 Million | 100.00% |
Laekna, Inc. Competitors by Market Cap
The table below lists competitors of Laekna, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ichia Technologies Inc
TW:2402
|
$359.51 Million |
|
Timbercreek Financial Corp
PINK:TBCRF
|
$359.55 Million |
|
Der International Home Furnishing Co Ltd
SHE:002631
|
$359.59 Million |
|
Hunan Baili Engineering Sci
SHG:603959
|
$359.90 Million |
|
Consolidated Communications
NASDAQ:CNSL
|
$359.25 Million |
|
Nederman Holding AB (publ)
PINK:NHOXF
|
$359.24 Million |
|
Actblue Co Ltd
SHE:300816
|
$359.19 Million |
|
Shanghai Newtouch Software Co. Ltd. A
SHG:688590
|
$359.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Laekna, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 803,972,000 to 804,792,000, a change of 820,000 (0.1%).
- Net loss of 254,296,000 reduced equity.
- New share issuances of 213,159,000 increased equity.
- Other factors increased equity by 41,957,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-254.30 Million | -31.6% |
| Share Issuances | €213.16 Million | +26.49% |
| Other Changes | €41.96 Million | +5.21% |
| Total Change | €- | 0.10% |
Book Value vs Market Value Analysis
This analysis compares Laekna, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.82x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-2.85 | €1.62 | x |
| 2022-12-31 | €-4.88 | €1.62 | x |
| 2023-12-31 | €2.06 | €1.62 | x |
| 2024-12-31 | €1.97 | €1.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Laekna, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-31.60%) is below the historical average (-19.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | €-637.85 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-591.09 Million |
| 2023 | -45.87% | 0.00% | 0.00x | 1.16x | €-449.21 Million |
| 2024 | -31.60% | 0.00% | 0.00x | 1.19x | €-334.78 Million |
Industry Comparison
This section compares Laekna, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Laekna, Inc. (4U4) | €712.86 Million | 0.00% | 0.28x | $359.35 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |